MedTrace Logo

Safety and Effectiveness of D-serine in Schizophrenia

NCT00322023 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2020-10-05

Study results available
· View outcomes & findings →

Summary

This study will determine whether increasing D-serine within the body will improve negative symptoms and cognitive impairments in people with schizophrenia.

Conditions

Interventions

DRUG

D-serine

D-serine at following dose levels: 30 mg/kg, 60 mg/kg, and 120 mg/kg. PK/PD studies done at day 1. Medication will be administered as powder dissolved in liquid given in two divided doses daily for 4 weeks.

DRUG

D-serine

DRUG

D-serine

DRUG

D-serine

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • Nathan Kline Institute for Psychiatric Research

    lead OTHER

Principal Investigators

  • Daniel C. Javitt, MD, PhD · Nathan Kline Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2009-01-31
Completion
2009-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00322023 on ClinicalTrials.gov